Form 4: Scholar Rock CHRO Granted Future RSUs

Scholar Rock's Chief Human Resources Officer, Caryn Parlavecchio, was granted 29,258 restricted stock units vesting over four years.

Summary

• Caryn Parlavecchio, Chief Human Resources Officer of Scholar Rock Holding Corp., was granted 29,258 Restricted Stock Units (RSUs).
• The transaction date for this grant is reported as February 9, 2026.
• These RSUs vest in four equal annual installments over four years, with the first installment vesting on January 15, 2027.
• Each RSU represents the contingent right to receive one share of the company's common stock upon vesting, provided continued service.
• Following this transaction, Ms. Parlavecchio beneficially owns a total of 178,122 securities, comprising 78,283 shares of common stock and 99,839 RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining key talent and aligning executive incentives with long-term shareholder value through equity grants.

Positives

• The grant of RSUs aligns management's interests with long-term shareholder value through time-based vesting.
• The significant RSU grant indicates continued commitment to the Chief Human Resources Officer, supporting executive retention.

Negatives

• No immediate cash compensation or direct stock purchase is involved, as the grant is for RSUs with a $0.00 price.
• The future vesting schedule means the value of the grant is contingent on future stock performance and continued employment.

Risks

• The ultimate value of the RSUs is subject to the future market price of Scholar Rock Holding Corp. common stock.
• Vesting of the RSUs is contingent on the reporting person's continued service relationship with the Issuer on each vesting date.

Future Outlook

The RSU grant with a multi-year vesting schedule indicates a long-term retention strategy for a key executive, suggesting stability in the human resources leadership. The future vesting dates extend through January 2030.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs) with multi-year vesting schedules, are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This aligns executive compensation with long-term company performance and shareholder interests, a common strategy among peers like Biogen or Vertex Pharmaceuticals.

Comparison to Industry Standards

• The use of RSUs for executive compensation is a common practice across the biotech industry, comparable to compensation structures at companies like Moderna or Regeneron.
• A four-year vesting schedule is typical for executive equity grants, providing long-term incentives similar to those seen at companies such as Gilead Sciences or Amgen.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to equity-based compensation.

Next Steps

• First annual installment of RSUs to vest on January 15, 2027.
• Subsequent annual installments to vest annually thereafter for three more years.

Key Dates

Recommendation

The RSU grant to a key executive is a standard compensation practice aimed at retaining talent and aligning interests with long-term shareholder value. It does not present new information that would significantly alter the company's financial outlook or operational performance, thus a "hold" recommendation is appropriate as it maintains the existing investment stance.

Keywords

Scholar Rock Holding Corp, SRRK, Restricted Stock Units, RSUs, Insider Transaction, Executive Compensation, Caryn Parlavecchio, Form 4, Equity Grant